New scientist article October 2015

A trial of anti cancer medication has helped bedridden ppl walk and talk for the first time in years, finds Jessica Hamzelou.

It is the first drug that seems to directly target the causes of Parkinson's disease. People taking part in a trial have had their symptoms reversed, allowing them to talk, get out of bed and feed themselves once again. Although there are already several treatments for the symptoms of Parkinson's, this could be the first to provide substantial, lasting relief.

"We've seen patients at end stages of the disease coming back to life," says Charbel Moussa of Georgetown university medical center in Washington DC, who led the trial.

The drug nilotinib, is already approved to treat cancer - it blocks a protein that drives chronic myeloid leukemia. But it also blocks a protein that interferes with lysosomes - cell structures that destroy harmful proteins.

Moussa thinks nilotinib can free up the lysosomes, which he calls the brains "garbage disposal system", to do a better job of clearing out the accumulation of proteins in the brain that is associated with Parkinson's disease. It is this build up of proteins that is thought to trigger the death of brain cells that make the molecules like dopamine needed for movement and other functions.

Tests in animals showed promise, so Moussa, his colleague Fernando Pagan and their team set up a small trial of 12 volunteers with Parkinson's disease or a similar condition called dementia with Lewy bodies. The trial was designed to test onl the safety of the drug, which was given as a daily oral dose for 6 months. All the volunteers were at an advanced stage of disease at the start of the trial. Three of the were unable to speak, and were enrolled in the study relatives with power of attorney. But once they started taking the drug, all the volunteers began to improve, some just 3 weeks later. One woman who was barely able to move her limbs at the start managed to feed herself after 5 months of treatment. "We had ppl as stiff as a board at the start of the study who were walking around, sitting down and bending their legs by the end, " says Moussa. "You could see the elation on their faces when they saw the improvement. There wasn't a dry eye in the room."

An Awakening

Alan Hoffman, who first showed signs of Parkinson's in 1997, says the nilotinib trial changed his life. Previously unable to get out of bed without help, within weeks of beginning the trial he was able to make the bed himself, and read a book for the first time in years. Pagan compares the improvements to those in neurologist Oliver Sack's book Awakenings - subsequently made into a film - in which he described helping ppl who had been paralysed for decades by sleeping sickness to move, walk and speak fluently again. "They were more fluent in speech, and had a lot more energy", says Pagan. All three participants who were unable to speak were talking again by the end of the trial. "It was like an awakening for them", says Pagan. Some volunteers found their drastic improvements to be too challenging, says Pagan. One woman dropped out of the trial because her husband struggled to cope with her new found energy, he says. "When a person is not able to verbalise, it's actually easier to look after them," he says. "Once this woman started to talk, she argued with her husband - it caused more of a caregiver burden."

The drug was detectable in the cerebral spinal fluid of the participants, which shows that it makes it through the blood-brain barrier and into the brain. The team also monitored the tau, amyloid beta and alpha-synuclien proteins that accumulate as part of Parkinson's disease, and found that the levels of proteins either stabalised or fell in all participants. At the same time, dopamine levels increased. Those taking the highest dose of the drug showed the biggest changes. Pagan presented the results on 17 October at the neuroscience 2015 meeting in Chicago. By one measure, participants' cognition improved by an average of around 5 points on a scale of 30.

While Nilotinib causes unpleasant side effects in ppl who take high doses of it for Leukemia, much lower doses were used in this trial and the team saw no unwanted effects. Graham Kerr art Queensland University of Technology in Brisbane, Australia, says the results are striking. " the new treatment certainly appears to alleviate symptoms of Parkinson's as well as cause reduction in boimarkers associated with disease progression," he says. The team thinks Nilotinib is the first drug that can target the root cause of Parkinson's disease and provide more than temporary relief. Other neurologists are excited by the results, but warn that no firm conclusions can be drawn until the drug has been tested in a larger trial with a control group taking a placebo. "It seems to good to be true. I dearly hope I am wrong" says Carl Clarke of Sandwell and West Birmingham Hospitals NHS Trust, UK.

"If It can really reverse Parkinson's, we'd have reached a major milestone, but I'm sceptical," says Kallol Ray Chaudhuri at Kings college London. "I'd say watch this space." There have been false dawns for Parkinsons before. A compound thought to encourage the growth of new brain cells - GDNF - received a lot of interest after promising animal experiments, and evidence suggesting it worked in a small number of ppl. However, no one has yet managed to replicate the effects in larger, placebo-controlled clinical trials.

The placebo effect can make a huge difference to symptoms of Parkinson's disease, says Arthur Roach, director of research at the charity Parkinson's UK. "We can't yet say that patients will benefit." He says a persons symptoms can also naturally vary by a large degree, for example at different times of the day.

Moussa's team is now enrolling ppl with a range of disorders that involve accumulating brain proteins, including Alzheimer's disease and ALS, for a larger placebo-controlled trial.

Sadly, the effect of nilotinib doesn't seem to last once ppl stop taking it, and when the trial ended, they started to deteriorate again, says Moussa. Many have since tried to get hold of the drug themselves, but it costs a whopping $10,000 a month. " one woman sold her car to buy the drug for her husband". Says Moussa. Pagan is in discussions with manufacturer Novartis, hoping that the participants can be offered continued treatment at a reduced cost on a companionate basis, through a procedure the company already uses to help ppl with cancer afford medication. "We've been working on it for 3 months", says Pagan, "and hope to have an answer soon".

Last edited by

11 Replies

  • Thinking about it, it must be VERY hard to suddenly have your loved one questioning your actions! To have them, making decisions, that's great, if they are more independent, but to have S questioning everything I do and make decisions, while still having to look after him 24/7. Well, that just wouldn't work!!!

    Lots of love


  • It sounds very hopeful but reading the cost of it i don't think we will get it on the nhs. Janexx

  • Our only real hope, is it helps people with Alzheimer's, then the price will drop dramatically!!!

    Lots of love


  • Too late for my darling. If the volunteers made so much progress, it was a bit cruel to them and their carers taking them off after 6 months. Who, in their right mind, would drop out of something that was improving them, whatever their carer thought. I'm thinking the same as Carl Clarke, too good to be true but certainly hope it is true, for all the PSP and Parkinson's sufferers of the future.


  • The drug must come down in price if it works for PD. Only 600 people are diagnosed with chronic myeloid leukaemia per year in the UK but about 10,000 are diagnosed with PD. The drug could become a gold mine!

  • Don't mean to sound cruel, but the NHS are allowed to spend what they like on Cancer sufferers, the rest of the evil diseases around, can go whistle!!!

    Before anyone shouts, my Grandfather and Father both died of Cancer. My sister and one uncle have survived. Another Uncle could well be taking this drug as he has Leukaemia!

    It's the improvement for Alzheimer's, that we have to pray for, (if this drug works for PSP,) because that really will tick the right box!!!

    Lots of love


  • A good friend of mine who had been a nurse was diagnosed with breast cancer and, a short while after PD. She said that she was more worried by the PD than the cancer even though her sister had died of breast cancer. With cancer you have a chance of a cure and doctors are interested in helping you. With PD, PSP, CBD, MSA there isn't cure and doctors etc just lose interest. Many of my PD friends feel abandoned and with the lesser known things like PSP the medical profession gives up. This is why these support groups are so important. K. Xx

  • Totally agree!!! I recently attended a Carers group, most had partners with Cancer. Although, they all had a terminal diagnoses, I didn't feel the sense of bereavement, that we all live with on a daily basis. I know with my Dad, he stayed being my Dad, even hours before he died. S is no longer the man I fell in love with, all those years ago! Although I did get a glimpse yesterday. I have an App, called Touch Voice, which he is managing to use! We had a small conversation about how I am going to alter the back patio, to get wheelchair assess for him! It's hard work getting him to use it, but when he does, it's like having him back!!!

    Lots of love


  • How lovely to be able to have a conversation! We always chatted all the time and would laugh at other couples sitting in stony silence. He "talks" for ages to the people who are not there in the room but it is not in English. I would love to talk to him again.

    Enjoy this tiny window of communication .

    Love Kathie

  • Looks like a great app :)

  • Thanks for the hopeful, encouraging report. I found the info below on the ALS forum (must register, so I pasted some of the post, in case you don't want to register). Here they discuss that a similar 'autophagy' response occurs when taking Trehalose ($9/lb supplement). I'm hoping to convince my sister to try the Trehalose while waiting for an available, affordable drug to come to the market.

    ".......We have found that trehalose significantly delays disease onset prolongs life span, and reduces motor neuron loss in the spinal cord of SOD1(G93A) mice. Most importantly, we have documented that trehalose decreases SOD1 and SQSTM1/p62 aggregation, reduces ubiquitinated protein accumulation, and improves autophagic flux in the motor neurons of SOD1(G93A) mice. Moreover, we have demonstrated that trehalose can reduce skeletal muscle denervation, protect mitochondria, and inhibit the proapoptotic pathway in SOD1(G93A) mice. Collectively, our study indicated that the MTOR-independent autophagic inducer trehalose is neuroprotective in the ALS model and autophagosome-lysosome fusion is a possible therapeutic target for the treatment of ALS.

    And on the other side of the cost spectrum from trehalose, there is nilotinib:

    An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson's disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University Medical Center (GUMC) in Washington. In addition, the drug, nilotinib (Tasigna® by Novartis), led to statistically significant and encouraging changes in toxic proteins linked to disease progression (biomarkers)."


You may also like...